Skip to content

INDEPENDENT EQUITY RESEARCH

  • The Program
  • Reports
  • About Us
  • Contact us
  • The Program
  • Reports
  • About Us
  • Contact us
  • The Program
  • Reports
  • About Us
  • Contact us

INDEPENDENT EQUITY RESEARCH

Read more about the article RedHill Biopharma Ltd.: RedHill gives up migraine product (RHB-103). Upside remains, but the price target is decreased to NIS 2.27.

RedHill Biopharma Ltd.: RedHill gives up migraine product (RHB-103). Upside remains, but the price target is decreased to NIS 2.27.

  • Post author:jaimeuss_admin
  • Post published:17 בSeptember 2018
  • Post category:Research

Continue ReadingRedHill Biopharma Ltd.: RedHill gives up migraine product (RHB-103). Upside remains, but the price target is decreased to NIS 2.27.
INDEPENDENT EQUITY RESEARCH

Tel: +972(0)9.950.2888
Email: equity.research@frost.com

Contact us

Copyright © 2020 Frost & Sullivan. All Rights Reserved.   Privacy Policy.

Accessibility by WAH